The FDA has restored GHK-Cu for non-injectable use to Category 1 of its 503A bulk drug substances list, reversing an April 22, 2026 removal that compounding pharmacies had been scrambling to interpret for the better part of a month
In other trials, results ranged from about 10% to 15% weight loss on average, depending on the dose and how strictly people followed lifestyle recommendations
Contact your supervising clinician promptly if you experience: Persistent or severe vomiting that prevents adequate fluid intake Signs of dehydration (dark urine, dizziness, confusion) Severe abdominal pain, particularly radiating to the back (which may indicate pancreatitis) Upper right abdominal pain, fever, or jaundice (which may indicate a gallbladder problem) The glucagon receptor activity of retatrutide means that blood glucose monitoring is particularly important for individuals with diabetes who are also taking insulin or sulphonylureas, as these combinations may increase the risk of hypoglycaemia (low blood sugar)
Intern Med 103 , 412 (2022)
Robert Lea is a science journalist in the U.K